← Eichor
Condition: Mds Mpn Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Mds Mpn

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
Phase 1/Phase 2 · 4 location(s) · Michael Savona · NCT04061421Caris Chromoseq Data Collection
Phase N/A · 1 location(s) · Caris Science, Inc. · NCT07680868Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative
Phase 1/Phase 2 · 7 location(s) · Jubilant Therapeutics Inc. · NCT07612280Anti-NKG2A Monoclonal Antibody for AML or MDS Patients Undergoing Haploidentical Transplantation
Phase 2 · 2 location(s) · Istituto Clinico Humanitas · NCT06892223Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction
Phase N/A · 1 location(s) · Peking University People's Hospital · NCT06211166A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patie
Phase 2 · 13 location(s) · Center for International Blood and Marrow Transplant Researc · NCT06859424Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantati
Phase 1 · 1 location(s) · Sawa Ito, MD · NCT07565220A Study of BGB-11417 in Participants With Myeloid Malignancies
Phase 1/Phase 2 · 46 location(s) · BeOne Medicines · NCT04771130A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Tria
Phase 3 · 143 location(s) · Celgene · NCT04064060Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05817955Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Phase N/A · 19 location(s) · Blueprint Medicines Corporation · NCT07143669Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MP
Phase 1 · 1 location(s) · Mayo Clinic · NCT05549661(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Phase 2 · 42 location(s) · Cogent Biosciences, Inc. · NCT04996875Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, M
Phase 1/Phase 2 · 1 location(s) · Uma Borate · NCT065235565-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies
EARLY_Phase 1 · 1 location(s) · Benjamin Tomlinson · NCT04187703A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Phase N/A · 142 location(s) · Center for International Blood and Marrow Transplant Researc · NCT01351545
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.